Cargando…

Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma

pH-sensitive drug carriers that are sensitive to the acidic (pH = ~6.5) microenvironments of tumor tissues have been primarily used as effective drug/gene/siRNA/microRNA carriers for releasing their payloads to tumor cells/tissues. Resistance to various drugs has become a big hurdle in systemic chem...

Descripción completa

Detalles Bibliográficos
Autores principales: Reddy, Teegala Lakshminarayan, Garikapati, Koteswara Rao, Reddy, S. Gopal, Reddy, B. V. Subba, Yadav, J. S., Bhadra, Utpal, Bhadra, Manika Pal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081533/
https://www.ncbi.nlm.nih.gov/pubmed/27786239
http://dx.doi.org/10.1038/srep35223
_version_ 1782462914826862592
author Reddy, Teegala Lakshminarayan
Garikapati, Koteswara Rao
Reddy, S. Gopal
Reddy, B. V. Subba
Yadav, J. S.
Bhadra, Utpal
Bhadra, Manika Pal
author_facet Reddy, Teegala Lakshminarayan
Garikapati, Koteswara Rao
Reddy, S. Gopal
Reddy, B. V. Subba
Yadav, J. S.
Bhadra, Utpal
Bhadra, Manika Pal
author_sort Reddy, Teegala Lakshminarayan
collection PubMed
description pH-sensitive drug carriers that are sensitive to the acidic (pH = ~6.5) microenvironments of tumor tissues have been primarily used as effective drug/gene/siRNA/microRNA carriers for releasing their payloads to tumor cells/tissues. Resistance to various drugs has become a big hurdle in systemic chemotherapy in cancer. Therefore delivery of chemotherapeutic agents and siRNA’s targeting anti apoptotic genes possess advantages to overcome the efflux pump mediated and anti apoptosis-related drug resistance. Here, we report the development of nanocarrier system prepared from kojic acid backbone-based cationic amphiphile containing endosomal pH-sensitive imidazole ring. This pH-sensitive liposomal nanocarrier effectively delivers anti-cancer drug (Paclitaxel; PTX) and siRNA (Bcl-2), and significantly inhibits cell proliferation and reduces tumor growth. Tumor inhibition response attributes to the synergistic effect of PTX potency and MDR reversing ability of Bcl-2 siRNA in the tumor supporting that kojic acid based liposomal pH-sensitive nanocarrier as efficient vehicle for systemic co-delivery of drugs and siRNA.
format Online
Article
Text
id pubmed-5081533
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-50815332016-10-31 Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma Reddy, Teegala Lakshminarayan Garikapati, Koteswara Rao Reddy, S. Gopal Reddy, B. V. Subba Yadav, J. S. Bhadra, Utpal Bhadra, Manika Pal Sci Rep Article pH-sensitive drug carriers that are sensitive to the acidic (pH = ~6.5) microenvironments of tumor tissues have been primarily used as effective drug/gene/siRNA/microRNA carriers for releasing their payloads to tumor cells/tissues. Resistance to various drugs has become a big hurdle in systemic chemotherapy in cancer. Therefore delivery of chemotherapeutic agents and siRNA’s targeting anti apoptotic genes possess advantages to overcome the efflux pump mediated and anti apoptosis-related drug resistance. Here, we report the development of nanocarrier system prepared from kojic acid backbone-based cationic amphiphile containing endosomal pH-sensitive imidazole ring. This pH-sensitive liposomal nanocarrier effectively delivers anti-cancer drug (Paclitaxel; PTX) and siRNA (Bcl-2), and significantly inhibits cell proliferation and reduces tumor growth. Tumor inhibition response attributes to the synergistic effect of PTX potency and MDR reversing ability of Bcl-2 siRNA in the tumor supporting that kojic acid based liposomal pH-sensitive nanocarrier as efficient vehicle for systemic co-delivery of drugs and siRNA. Nature Publishing Group 2016-10-27 /pmc/articles/PMC5081533/ /pubmed/27786239 http://dx.doi.org/10.1038/srep35223 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Reddy, Teegala Lakshminarayan
Garikapati, Koteswara Rao
Reddy, S. Gopal
Reddy, B. V. Subba
Yadav, J. S.
Bhadra, Utpal
Bhadra, Manika Pal
Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma
title Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma
title_full Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma
title_fullStr Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma
title_full_unstemmed Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma
title_short Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma
title_sort simultaneous delivery of paclitaxel and bcl-2 sirna via ph-sensitive liposomal nanocarrier for the synergistic treatment of melanoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081533/
https://www.ncbi.nlm.nih.gov/pubmed/27786239
http://dx.doi.org/10.1038/srep35223
work_keys_str_mv AT reddyteegalalakshminarayan simultaneousdeliveryofpaclitaxelandbcl2sirnaviaphsensitiveliposomalnanocarrierforthesynergistictreatmentofmelanoma
AT garikapatikoteswararao simultaneousdeliveryofpaclitaxelandbcl2sirnaviaphsensitiveliposomalnanocarrierforthesynergistictreatmentofmelanoma
AT reddysgopal simultaneousdeliveryofpaclitaxelandbcl2sirnaviaphsensitiveliposomalnanocarrierforthesynergistictreatmentofmelanoma
AT reddybvsubba simultaneousdeliveryofpaclitaxelandbcl2sirnaviaphsensitiveliposomalnanocarrierforthesynergistictreatmentofmelanoma
AT yadavjs simultaneousdeliveryofpaclitaxelandbcl2sirnaviaphsensitiveliposomalnanocarrierforthesynergistictreatmentofmelanoma
AT bhadrautpal simultaneousdeliveryofpaclitaxelandbcl2sirnaviaphsensitiveliposomalnanocarrierforthesynergistictreatmentofmelanoma
AT bhadramanikapal simultaneousdeliveryofpaclitaxelandbcl2sirnaviaphsensitiveliposomalnanocarrierforthesynergistictreatmentofmelanoma